Is Lyka Labs a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Lyka Labs Ltd is a average quality company .

Is Lyka Labs undervalued or overvalued?

The key valuation ratios of Lyka Labs Ltd's currently when compared to its past seem to suggest it is in the Fair zone .

What is Lyka Labs share price return in the past 10 years?

Lyka Labs Ltd share price has appreciated 18.9% annually (CAGR) over the past ten years.

Is Lyka Labs a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Lyka Labs Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

Lyka Labs Ltd - Stock Valuation and Financial Performance

Name: Lyka Labs
Brand: Lyka Labs

BSE: 500259 | NSE: LYKALABS | Pharmaceuticals & Drugs | Small Cap

Place order

Lyka Labs Share Price

₹149.65 -4.80 -3.11%
as on 20-Dec'24 16:59

10 Year X-Ray of Lyka Labs:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Jun'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
ROCE % ⓘ	11.6%	10.5%	9%	-1.8%	-0.7%	-20.9%	4.5%	47.3%	-1%	2.5%	-
Value Creation Index ⓘ	-0.2	-0.3	-0.4	-1.1	-1.1	-2.5	-0.7	2.4	-1.1	-0.8	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	90.5	76.4	78	41.7	41.2	40.7	62.3	164	80.6	106	130
Sales YoY Gr.	-	-15.6%	2.2%	-46.6%	-1.2%	-1.1%	52.8%	164%	-51%	32%	-
Adj EPS ⓘ	-0.6	3	0.4	-3.6	0.7	-13.8	-4.9	14	-2.8	-0.8	1.1
YoY Gr.	-	NA	-88.4%	-1128.6%	NA	-2036.6%	NA	NA	-119.8%	NA	-
BVPS (₹) ⓘ	26.3	38	33.4	34.1	34.8	6.6	1.5	15.5	19.2	27.3	36.6
Adj Net Profit ⓘ	-1.3	6.7	0.8	-10.1	2	-39.4	-13.9	40.2	-8.5	-2.5	4
Cash Flow from Ops. ⓘ	29.1	10.3	20.2	6.8	18.3	-11.5	5.8	76.5	6.9	3.1	-
Debt/CF from Ops. ⓘ	3.7	13.6	5.6	14.9	5	-12	28.1	1.7	10.4	18.4	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	1.8%	20.9%	19.6%	32%
Adj EPS ⓘ	NA	-201.4%	NA	NA
BVPSⓘ	0.4%	-4.7%	160.7%	41.9%
Share Price	18.9%	47.8%	-13.5%	25.2%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Jun'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Return on Equity % ⓘ	-2	7.8	1.1	-11.9	2.1	-67.2	-120.2	164.5	-14.1	-2.9	3.5
Op. Profit Mgn % ⓘ	21.7	13.3	27.9	-1.2	2.2	-7.9	23.2	59.3	19.4	13.7	13.5
Net Profit Mgn % ⓘ	-1.4	8.7	1	-24.3	4.9	-96.8	-22.4	24.5	-10.6	-2.4	3.1
Debt to Equity ⓘ	1.9	1.6	1.5	1.1	0.9	7.3	36.7	2.9	1.2	0.6	0.2
Working Cap Days ⓘ	299	461	301	602	633	493	230	101	247	214	74
Cash Conv. Cycle ⓘ	-55	-54	-50	91	129	62	-25	-6	70	65	23

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 19.56%

Debt to equity has declined versus last 3 years average to 0.63

Sales growth is good in last 4 quarters at 54.41%

Return on Equity has declined versus last 3 years average to 3.50%

Net Profit has been subdued in last 3 years 0.00%

Latest Financials - Lyka Labs Ltd.

	Standalone	Consolidated
TTM EPS (₹)	1.1	0.9
TTM Sales (₹ Cr.)	130	132
BVPS (₹.) ⓘ	36.6	27.7
Reserves (₹ Cr.) ⓘ	95	63
P/BV ⓘ	4.08	5.40
PE ⓘ	134.67	167.43

From the Market
52 Week Low / High (₹)	99.95 / 175.95
All Time Low / High (₹)	8.46 / 267.20
Market Cap (₹ Cr.)	534
Equity (₹ Cr.)	35.7
Face Value (₹)	10
Industry PE ⓘ	44.3

Management X-Ray of Lyka Labs:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

5.53

5.12

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Lyka Labs

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Lyka Labs

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Jun'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Sales	90	57	78	42	41	41	62	164	81	106
Operating Expenses ⓘ	71	50	56	42	40	44	48	67	65	92
Manufacturing Costs	3	2	3	3	3	6	6	8	9	8
Material Costs	51	34	36	22	22	20	24	31	29	43
Employee Cost	10	7	10	11	10	12	13	16	17	26
Other Costs ⓘ	7	7	7	7	5	7	5	12	10	14
Operating Profit ⓘ	20	8	22	-1	1	-3	14	97	16	15
Operating Profit Margin (%)	21.7%	13.3%	27.9%	-1.2%	2.2%	-7.9%	23.2%	59.3%	19.4%	13.7%
Other Income ⓘ	2	12	2	2	3	3	2	3	3	2
Interest ⓘ	20	13	17	8	6	19	26	20	12	5
Depreciation ⓘ	4	3	6	6	4	8	8	15	14	12
Exceptional Items ⓘ	4	1	-2	1	-1	-28	-1	-5	-7	0
Profit Before Tax ⓘ	1	5	-1	-11	-7	-55	-18	60	-13	-1
Tax ⓘ	0	0	0	0	-9	0	-4	20	0	1
Profit After Tax	1	5	0	-11	2	-55	-14	40	-13	-2
PAT Margin (%)	1.5%	8.4%	-0.2%	-26.0%	4.2%	-135.0%	-23.2%	24.3%	-16.5%	-2.1%
Adjusted EPS (₹)	0.6	2.2	-0.1	-3.9	0.6	-19.3	-5.0	13.9	-4.3	-0.7
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Jun'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Shareholders Fund	61	67	74	96	98	19	4	44	59	90
Share Capital ⓘ	23	23	22	28	28	29	29	29	31	33
Reserves ⓘ	38	43	52	68	70	-10	-24	16	28	57
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	65	72	73	40	91	136	161	82	71	55
Long Term Debt	29	25	35	5	79	126	151	62	63	43
Short Term Debt	36	46	38	36	12	11	10	20	8	12
Trade Payables	39	30	28	21	22	17	12	9	8	11
Others Liabilities ⓘ	68	60	67	86	27	37	20	74	41	30
Total Liabilities ⓘ	233	228	242	243	238	209	197	209	179	186
Fixed Assets
Gross Block	98	100	93	94	93	141	163	172	154	156
Accumulated Depreciation	37	40	7	13	17	39	68	82	88	100
Net Fixed Assetsⓘ	62	60	86	81	76	102	95	90	66	56
CWIP ⓘ	27	30	24	26	30	26	24	18	16	23
Investmentsⓘ	63	63	62	62	62	32	32	32	32	32
Inventories	13	7	9	7	6	6	4	8	7	10
Trade Receivables	29	26	24	30	30	7	10	18	17	26
Cash Equivalents	2	2	1	0	0	8	7	15	9	6
Others Assetsⓘ	39	40	34	35	34	28	24	27	32	34
Total Assets ⓘ	233	228	242	243	238	209	197	209	179	186

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Jun'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ	29	8	20	7	18	-11	6	77	7	3
PBT ⓘ	1	5	-1	-11	-7	-55	-18	60	-13	-1
Adjustment ⓘ	18	3	22	12	10	55	34	38	31	17
Changes in Working Capital ⓘ	10	-0	-0	7	15	-12	-9	-21	-11	-11
Tax Paid ⓘ	-1	0	-1	0	0	1	-1	-1	0	-1
Cash Flow From Investing Activity ⓘ	29	5	-5	-3	-3	0	0	-4	7	-9
Capex	28	-5	-5	-3	-3	-1	-1	-6	6	-9
Net Investments	0	0	0	0	0	0	0	0	0	0
Others ⓘ	0	10	0	0	0	1	1	2	1	1
Cash Flow From Financing Activityⓘ	-63	-13	-15	-4	-16	20	-8	-63	-20	3
Net Proceeds from Shares ⓘ	0	0	0	34	0	2	0	0	45	25
Net Proceeds from Borrowing ⓘ	0	0	10	-31	74	28	0	-50	-46	-18
Interest Paid ⓘ	-19	-11	-16	-6	-6	-6	-6	-22	-10	-7
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	-44	-2	-8	-1	-84	-4	-1	9	-10	3
Net Cash Flow ⓘ	-5	0	0	-1	0	8	-2	9	-7	-3

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Jun'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Ratios
ROE (%)	2.38	8.07	-0.27	-12.78	1.79	-94.98	-124.71	163.37	-25.69	-3.04
ROCE (%)	11.62	10.47	9.01	-1.8	-0.7	-20.89	4.45	47.25	-1.02	2.54
Asset Turnover Ratio	0.39	0.26	0.36	0.18	0.17	0.18	0.31	0.81	0.42	0.58
PAT to CFO Conversion(x)	29	1.6	N/A	N/A	9	N/A	N/A	1.93	N/A	N/A
Working Capital Days
Receivable Days	102	166	109	234	266	162	48	31	79	74
Inventory Days	40	59	35	71	59	52	29	14	34	28
Payable Days	266	372	293	419	356	359	221	122	106	81

Lyka Labs Ltd Stock News

Lyka Labs Ltd FAQs

What is the share price of Lyka Labs?

Company share prices are keep on changing according to the market conditions. The closing price of Lyka Labs on 20-Dec-2024 16:59 is ₹149.7.

What is the market cap of Lyka Labs?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 20-Dec-2024 16:59 the market cap of Lyka Labs stood at ₹534.1.

What is the P/E ratio of Lyka Labs?

The latest P/E ratio of Lyka Labs as of 20-Dec-2024 16:59 is 134.7.

What is the P/B ratio of Lyka Labs?

The latest P/B ratio of Lyka Labs as of 20-Dec-2024 16:59 is 4.08.

What is the 52-week high and low of Lyka Labs?

The 52-week high of Lyka Labs is ₹175.9 and the 52-week low is ₹99.95.

What is the TTM revenue of Lyka Labs?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Lyka Labs is ₹129.7 ( Cr.) .

About Lyka Labs Ltd

Lyka Labs Ltd was incorporated on December 29, 1976 as a private limited company and converted into a public limited company on December 19, 1985.

The company is engaged in the manufacture of pharmaceutical products. It also manufactures Veterinary products including injections, powders, creams and suspensions. The company offers various surgical disposables, such as syringes, surgical blades, cotton crepe bandage and first aid kits.

Lyka Labs is committed to creating a better tomorrow for India. Maintaining a core competency in Lyophilization, allows Lyka Labs to supply Freeze Dried Drugs in sufficient quantities with the right quality. Lyka strives to manage this business in an ethical and transparent manner.

Lyka has 2 manufacturing facilities in Ankleshwar and Tarapur. There is also an R & D facility based in Chakala, Mumbai, and a corporate head office based in Andheri, Mumbai.

Plant located at Ankleshwar, Gujarat is one of the largest chemical Industrial estates in Asia. Located approx. 10 kms from the city of Bharuch, Gujarat. Ankleshwar is well connected and can be reached by road, rail or air from Mumbai, or by road and rail from Vadodara, or Ahmedabad.

Tarapur Plant is located in the MIDC Industrial Estate in Tarapur, District Thane, Maharashtra. Located approximately 80 kms from Mumbai City, and well connected by rail and road to Mumbai.

Different business lines of the company:

Contract Manufacturing - Lyka undertakes manufacturing activities for a number of different companies on a Principal to Principal Basis. In most cases Lyka would undertake the entire manufacturing process, from sourcing of raw materials to manufacture to packaging, although Lyka also offers job work services where the raw materials are sourced by the client company. Their manufacturing processes are in line with world over best practices, as demonstrated by the ISO 9001:2002 Certification
Hospital Division - LYKA has forayed into marketing of products into hospitals/ institutions. To begin with, it has introduced a range of anti-infectives, which include systemic antimalarial, antifungal and antibacterials for serious infections. Apart from this, it has also introduced anesthetics, anti-ulcerants and steroid in parenteral dosage forms. On the anvil is the expansion of the range of the products in the above therapeutic segments as well as in the new therapeutic segments. The company also has plan to introduce products in solid dosage forms for hospitals / institutions.
Lyka Animal Health Care - Lyka Animal Healthcare Division within a short period has made strong presence in Indian Veterinary market with their quality innovative products. The animal healthcare division is managed and headed by veterinary professional with strong and dedicated team of field and in-house persons.
Generics - When generic products become available, the market competition often leads to substantially lower prices for both the original brand name product and the generic forms. Lyka markets branded generic products in the form of: -Tablets -Capsules -Ointments -Syrups Dry Powder and Liquids
Lyka BDR- Lyka manufactures and sells products to its Joint Venture company Lyka BDR. Lyka BDR is the largest seller of human and veterinary products in Sudan

Product range of the company includes:

Ampholyn Inj.
Hydrolin Inj.
Lyom Inj.
Lypan Inj.
Lypitaz Inj. 2.25g
Lypitaz Inj. 4.5g
Lyrab Inj.
Lysunate Inj.
Lysunate Tabs
Lyvec Inj.
Merojet Inj. 500mg
Merojet Inj.1000mg
Stropaz Inj.
Thiolyn Inj. 500mg
Thiolyn Inj.1000mg
Vancolym Inj.
Xolycef - SB Inj.
Xolycef - TZ Inj.
Xolycef Inj. 1000mg
Zimtaz Inj.

Achievements/ recognition:

ISO 9001:2000 certified
Recognized as in-house R&D Centre by Government of India, Ministry of Science & Technology, Department of Scientific and Industrial Research.
In 2011 the company has been conferred Certificate of Appreciation Patent Award by Pharmaceuticals Export Promotion Council.